Reactions including allergic asthma with dyspnea as well as rare anaphylactic/anaphylactoid shock observed. A transient (usual duration <10 days) exacerbation of the signs and symptoms of the disease process may be observed with the initiation of therapy. The development of pituitary adenomas may rarely be seen with long-term therapy. Use caution in history of depression. Reduced glucose tolerance noted in rare cases. A transient exacerbation of the signs/symptoms of endometriosis may occur. Oral contraceptives should be discontinued prior to starting therapy. Increases in blood pressure (including hypertensive crisis) may occur in patients being treated for hypertension. Treatment inducing a hypoestrogenic state may lead to changes in bone density. Use of buserelin for >6 months or in association with other risk factors may contribute to additional bone loss. Initiation of therapy without a concomitant antiandrogen agent may lead to a transient worsening of symptoms including bone pain, weakness of leg muscles, impaired micturition, hydronephrosis, lymphostasis, or thrombosis with pulmonary embolus. In prostatic disease, a transient increase in symptoms may occur early in therapy.